Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)

CAPS Rating: 4 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar CrackerJack99 (96.85) Submitted: 5/3/2011 2:27:59 PM : Outperform Start Price: $2.22 AEZS Score: -75.62

UltraLong

Report this Post Reply

Featured Broker Partners


Advertisement